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Introduction
Phthalates are human-made chemicals 
used globally in production of commercial 
and industrial goods (Meeker et al. 2009). 
Phthalates are primarily used as plasticizers 
in the manufacture of flexible vinyl and poly-
vinyl chloride plastic, but are also used in 
personal care products, pharmaceuticals, tex-
tiles, medical supplies, and many other prod-
ucts [U.S. Environmental Protection Agency 
(EPA) 2007]. Because they are not covalently 
bound to the product matrix, phthalates 
can leach into the surrounding environment 
(U.S. EPA 2007). Exposure to phthalates can 
occur through ingestion, inhalation, intra-
venous, or dermal exposure (Meeker et al. 
2009; Sathyanarayana 2008). Because of their 
widespread use, phthalates are ubiquitous in 
the environment, and nationally representa-
tive studies have demonstrated widespread 
exposure to multiple phthalates in the U.S. 
population [Centers for Disease Control and 
Prevention (CDC) 2012a; Silva et al. 2004a].
Concern has been raised over potential 
endocrine-disrupting properties of phthal-
ates (Crisp et al. 1998; U.S. EPA 2007), 
particularly evidence suggesting anti-
androgenic effects during prenatal develop-
ment (Meeker et al. 2009; Swan et al. 2005). 
A less studied area of public health importance 
is the potential neurobehavioral effects of pre-
natal exposure to phthalates. Fetal brain devel-
opment is tightly regulated by the maternal 
endocrine system (Moore and Persaud 2003). 
Phthalates and other endocrine-disrupting 
chemicals may perturb this hormonal balance 
and disrupt fetal brain development (Zoeller 
and Crofton 2000).
Two studies of prenatal phthalate expo-
sure and neonatal behavior have focused on 
infants 5 days and 5 weeks after delivery, 
respectively (Engel et al. 2009; Yolton et al. 
2011). Both studies suggest that phthalate 
metabolite concentrations may be associated 
with alertness, motor control, arousal, and 
other behaviors, and lend support to examin-
ing these relationships in older children. To 
date, two studies have examined relationships 
between prenatal phthalate exposure and 
neurobehavioral development during child-
hood. A 2010 study reported that among 
171 children 4–9 years of age, higher prenatal 
urine concentrations of low-molecular weight 
phthalates [including di-n-butyl phthalate 
(DnBP) and diisobutyl phthalate (DiBP) 
(referred therein as dibutyl phthalates; DBPs) 
and diethyl phthalate (DEP)] were associated 
with higher scores for aggression, conduct 
problems, and depressive symptoms, but 
lower scores for emotional control, attention, 
and executive function based on parental sur-
veys (Engel et al. 2010). Sex-stratified analy-
ses revealed elevated coefficients among males 
for several of these outcome scores. More 
recently, Whyatt set al. (2012) reported that 
prenatal urinary concentrations of phthalate 
metabolites were associated with higher scores 
for emotional reactivity, somatic complaints, 
withdrawn behavior, and a summary mea-
sure of internalizing behavior in 3-year old 
children (Whyatt et al. 2012). These asso-
ciations varied between boys and girls; spe-
cifically, metabolites of DBPs were associated 
with higher scores for emotional reactivity, 
somatic complaints, and withdrawn behavior 
in boys, whereas greater concentrations of 
a benzyl butyl phthalate (BzBP) metabolite 
were associated with higher scores for anxi-
ety/depressive behavior, somatic complaints, 
and withdrawn behavior in girls. Somatic 
complaints and withdrawn behavior were 
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Background: There is concern over potential neurobehavioral effects of prenatal phthalate 
exposures, but available data are inconsistent.
oBjectives: We examined associations between prenatal urinary concentrations of phthalate 
metabolites and neurobehavioral scores among children.
Methods: We measured phthalate metabolite concentrations in urine samples from 153 pregnant 
participants in the Study for Future Families, a multicenter cohort study. Mothers completed the 
Child Behavior Checklist when the children were 6–10 years of age. We estimated overall and sex-
specific associations between phthalate concentrations and behavior using adjusted multiple regres-
sion interaction models.
results: In boys, concentrations of monoisobutyl phthalate were associated with higher scores for 
inattention (β = 0.27; 95% CI: 0.04, 0.50), rule-breaking behavior (β = 0.20; 95% CI: 0.01, 0.38), 
aggression (β = 0.34; 95% CI: 0.09, 0.59), and conduct problems (β = 0.39; 95% CI: 0.20, 0.58), 
whereas the molar sum of di(2-ethylhexyl) phthalate metabolites was associated with higher scores 
for somatic problems (β = 0.15; 95% CI: 0.03, 0.28). Higher monobenzyl phthalate concentrations 
were associated with higher scores for oppositional behavior (β = 0.16; 95% CI: 0.01, 0.32) and 
conduct problems (β = 0.21; 95% CI: 0.06, 0.37) in boys, but with reduced anxiety scores in girls 
(β = –0.20; 95% CI: –0.39, –0.01). In general, the associations reported above were close to the 
null among girls. Model coefficients represent the difference in the square root–transformed out-
come score associated with a 1-unit increase in log-transformed metabolites.
conclusions: Our results suggest associations between exposure to certain phthalates in late preg-
nancy and behavioral problems in boys. Given the few studies on this topic and methodological and 
population differences among studies, additional research is warranted.
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positively associated with mono-n-butyl 
phthalate (MBP) in boys and girls.
In summary, results from the few published 
studies suggest associations between prenatal 
phthalate exposure and children’s neurodevel-
opment. However, given the variety of study 
populations, age groups, and neurobehavioral 
instruments employed in these studies, addi-
tional investigation is warranted. Therefore, in 
this analysis we examined associations between 
urinary prenatal phthalate metabolites con-
centrations and neurobehavioral scores among 
 children 6–10 years of age.
Methods
Study population. The mothers included in 
this analysis were originally recruited in 1999–
2005 into the Study for Future Families (SFF), 
a multicenter pregnancy cohort study (Swan 
et al. 2003, 2005). A total of 961 pregnant 
mothers and partners were recruited from 
California, Minnesota, Missouri, and Iowa. 
Of these, 441 mothers agreed to be recon-
tacted and were eligible for follow-up. Prenatal 
phthalate metabolite concentrations measured 
in maternal spot urine samples (obtained at 
mean gestational age of 26.6 ± 7.2 weeks; 
range, 10–39) were available for 380 of these 
mothers. In 2010, we recontacted SFF mothers 
of children born in 2000–2005. Mothers were 
asked to complete neurodevelopmental assess-
ments, including the Child Behavior Checklist 
(CBCL); 176 mothers completed these assess-
ments. Children were excluded from the pres-
ent analysis because of incomplete covariate 
data (n = 8) or serious disability (n = 1). In 
addition, we excluded 14 children who were 
5 years old at the time of assessment because 
the CBCL version we used is normed for 
 children 6–10 years.
Ultimately, we analyzed data from 153 
children with complete information on their 
mothers’ prenatal phthalate metabolite uri-
nary concentrations, neurobehavioral scores, 
and covariates. Institutional review boards 
at all participating institutions approved 
all study procedures, and all participants 
signed informed consents for each study. 
The involvement of the CDC laboratory was 
determined not to constitute engagement in 
human subject research.
Maternal urinary phthalate metabolite 
concentrations. Urinary phthalate metabolites 
were quantified at the Division of Laboratory 
Sciences, National Center for Environmental 
Health, CDC, by solid phase extraction–
high-performance liquid chromatography–
isotope dilution tandem mass spectrometry. 
Further details of the analyses are available 
elsewhere (Silva et al. 2004b; Swan et al. 
2005). Creatinine was measured also at CDC 
using an enzymatic reaction.
We included seven phthalate metabolites 
that are often studied for their health effects. 
We considered three metabolites of di(2-ethyl-
hexyl) phthalate (DEHP): mono(2-ethylhexyl) 
phthalate (MEHP), mono(2-ethyl-5-hydroxy-
hexyl) phthalate (MEHHP), and mono(2-
ethyl-5-oxohexyl) phthalate (MEOHP); and 
two metabolites of DBPs: monoisobutyl 
phthalate (MiBP) and MBP. We also consid-
ered monobenzyl phthalate (MBzP), a metabo-
lite of BzBP, and monoethyl phthalate (MEP), 
a metabolite of DEP. We calculated molar 
sums of the three DEHP metabolites to obtain 
a summary measure of DEHP using a previ-
ously reported technique (Wolff et al. 2008). 
For example, the molar sum of the three mea-
sured DEHP metabolites was calculated by 
dividing the concentration of each metabolite 
by its molar mass and summing the results: 
∑DEHP = MEHP × (1/278.34) + MEHHP × 
(1/294.34) + MEOHP × (1/292.33). The limit 
of detection (LOD) for all metabolites was 
between 0.95 and 1.07 ng/mL. Concentrations 
that were flagged as below the LOD were 
assigned the value of LOD divided by the 
square root of 2, as previously recommended 
(Hornung and Reed 1990).
Neurobehavioral assessment. Mothers 
rated their child’s behavior with the School-
age CBCL, an extensively validated neuro-
developmental survey instrument (Achenbach 
and Rescorla 2001; Greenbaum et al. 2003; 
Kamphaus and Frick 2010). The CBCL 
yields seven syndrome scale scores including: 
Anxious/Depressed, Withdrawn/Depressed, 
Somatic Complaints, Social Problems, 
Thought Problems, Attention Problems, Rule-
breaking Behavior, and Aggressive Behavior. 
These individual syndrome scores were com-
bined to produce three summary measures of 
internalizing behavior, externalizing behav-
ior, and a total problems score. In addition, 
the CBCL includes items consistent with 
DSM-IV (Diagnostic and Statistical Manual 
of Mental Disorders, Fourth Edition; American 
Psychiatric Association 2000) cate gories. 
DSM-oriented scale scores include: Affective 
Problems, Anxiety Problems, Somatic 
Problems, Attention Deficit/Hyperactivity 
Problems (ADHD), Oppositional/Defiant 
Problems, and Conduct Problems. The CBCL 
syndrome scales were derived empirically via 
factor analytic whereas the DSM-oriented 
scales were constructed to be consistent with 
DSM-IV diagnostic criteria, through expert 
consensus (Achenbach et al. 2003). In psycho-
metric analysis, these DSM-oriented scales 
have been found to be highly reliable and dis-
played convergent and discriminative validity 
(Nakamura et al. 2009). In cases where syn-
drome and DSM-oriented scales overlap (e.g., 
the Somatic Complaints syndrome scale and 
the Somatic Problems DSM-oriented scale), 
correlations between scale types were high 
despite the difference in construction method-
ologies (Achenbach et al. 2003).
The CBCL provides raw scores for each 
of the scales, computed by summing parent 
ratings (0 = “not true,” 1 = “somewhat true,” 
2 = “often true”) for the individual items of 
each scale. Higher raw scores indicate adverse 
behavior. The response categories are equally 
weighted, such that a child could reach a score 
of 8 by having four items endorsed as “often 
true” or eight items endorsed as “somewhat 
true.” The CBCL software uses individual 
scale and summary measure raw scores to 
compute T-scores based on a normative sam-
ple of children, accounting for age and sex. 
T-scores are calculated such that raw scores 
at or below the median value are assigned a 
value of 50 (except for the three summary 
measures, which were not truncated). Thus, 
individual scale T-scores are left-truncated and 
positively skewed.
Whether researchers should analyze CBCL 
raw scores or T-scores is a point of discussion 
in child development literature (Drotar et al. 
1995). In this analysis, we reported the results 
of models using raw scores for two reasons. 
First, it allowed us to detect subtle associations 
of phthalate exposure with child behavior. 
Second, the use of raw scores satisfied regres-
sion model assumptions, whereas the use of 
T-scores, even with transformations, strongly 
violated these assumptions.
Statistical analysis. We calculated uni-
variate, descriptive statistics (mean, SD, mini-
mum, median, maximum, or frequencies if 
applicable) for all covariates and CBCL scores. 
Because of the approximate log-normal distri-
bution of urinary phthalate metabolite con-
centrations, we report geometric means (with 
accompanying 95% CIs) as well as the 25th 
and 75th percentile values. We also calculated 
correlations between metabolites (adjusting 
for creatinine).
We fit linear regression models both with 
and without sex × phthalate interactions to 
examine sexual dimorphism. We reported 
both sets of results regardless of the signifi-
cance of the interaction, as others have done 
(Sagiv et al. 2012). The first model estimated 
the overall associations between phthalate 
metabolite concentrations and CBCL scores, 
assuming a common slope for boys and girls. 
The second model allowed separate slopes 
for boys and girls by the inclusion of a sex × 
phthalate interaction and allowed us to esti-
mate the significance of the interaction. Using 
a re-parameterization of the same model, we 
estimated sex-specific slopes. This model was 
advantageous because it permitted sex-specific 
estimates without the need to stratify our 
sample and reduce power.
In each of these models, phthalate varia-
bles were natural-log transformed. Regression 
assumptions (e.g., normality of residuals, 
homoscedasticity) were checked for all  models. 
Given these diagnostics, we square-root 
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transformed all CBCL raw scores to stabi-
lize the residual variance. We adjusted for 
covariates thought to confound the associ-
ation of interest or to strongly predict the 
CBCL score. Covariates included child sex, 
child age at time of CBCL assessment (in 
months), mother’s education level (at least a 
college education vs. less than college educa-
tion), and urinary creatinine. In addition, we 
included a summary measure of family stress. 
The life events questions were derived from 
two validated questionnaires (Dohrenwend 
et al. 1978; Holmes and Rahe 1967). Both 
parents were asked whether any of the follow-
ing life events occurred during the pregnancy: 
a) job loss, b) serious illness/injury in family, 
c) death of close family member, d) relation-
ship difficulties with partner, e) legal/ financial 
problems, or f) any other major event. 
Mothers and partners received one point for 
each life event that was endorsed. Life event 
data was available for the partners of all moth-
ers in the study. All 12 life event items (six 
from each parent) were then summed to cre-
ate a summary measure of prenatal stress. We 
did not adjust our primary models for study 
center, but did perform sensitivity analyses to 
evaluate the influence of adjustment for study 
center on model estimates. We did not adjust 
for race/ethnicity because > 90% of the final 
sample was non-Hispanic white. However, 
we repeated models after restricting the analy-
sis to non-Hispanic white participants as a 
sensitivity analysis. In addition, we conducted 
a sensitivity analysis to examine the poten-
tial for confounding due to co-exposure to 
multiple phthalates by repeating regression 
analysis while adjusting for both molar sum 
DEHP and molar sum DBPs.
To ease interpretability, we calcu-
lated predicted percent change in CBCL 
raw scores (back-transformed into original 
raw score scale) between prenatal phthalate 
exposure at the 75th and 25th percentiles, 
holding covariates at their mean values. Our 
analysis was conducted with R version 2.15.2 
(R Foundation for Statistical Computing, 
Vienna, Austria). For all analyses, results were 
considered significant at p ≤ 0.05.
Results
Descriptive statistics on demographics and 
covariates are shown in Table 1. The final 
sample of 153 children included 77 boys 
and 76 girls (Table 1). The mean age of 
mothers at the time of the entry into SFF 
was 31.1 years (range, 18–42.3); and at the 
time of behavioral assessment, the mean age 
of the children was 102 months (8.5 years) 
(range, 72–126 months). Most mothers were 
at least college educated (85%). The mean 
family stress score was 1.4 (range, 0–8). Most 
mothers classified  themselves as non-Hispanic 
white (92%).
The phthalate metabolite concentrations 
we observed (Table 2) were comparable to 
those of a nationally representative sample of 
women of reproductive age (Kobrosly et al. 
2012). As expected, all phthalate metabolite 
concentrations were positively skewed. Levels 
appeared to be similar between boys and girls 
except for MEP concentrations, which were 
slightly higher among boys. The proportions 
of metabolite observations below the LOD 
were 5% for all metabolites other than MEHP 
(21% < LOD) and MiBP (18% < LOD). 
Correlations between DEHP metabolites were 
high (Pearson r = 0.72–0.98), and the correla-
tion between the DBP metabolites (MiBP and 
MBP) was moderate (Pearson r = 0.51) (see 
Supplemental Material, Table S1).
Using chi-square tests and t-tests, we 
compared covariate and phthalate concentra-
tions between our final sample (n = 153) and 
data from 359 of the 441 mothers who were 
eligible for follow-up after the first phase of 
SFF (see Supplemental Material, Table S2). 
These groups did not differ significantly with 
regard to baseline family stress (p = 0.15) 
or any phthalate metabolite concentrations. 
However, the children in the final sample had 
mothers with higher education (p = 0.005) 
and older age (p = 0.04), and were more likely 
to be non-Hispanic white (p = 0.03).
Raw CBCL scores for each category were 
positively skewed (Table 2). Male children 
exhibited higher raw scores (adverse behavior) 
than females on all categories of the syndrome 
scale. The same was true for most categories 
of the DSM-oriented scale. In addition to 
the raw scores, we calculated T-scores for 
the CBCL syndrome and DSM-oriented 
scales that indicate how scores for the study 
population compare with normative scores 
for children of the same age and sex. Mean 
percentiles across all outcomes ranged from 
59.79% to 65.5%, which suggests that our 
study population had a higher prevalence 
of behavioral problems compared with the 
CBCL normative sample.
DEHP molar sum. Table 3 presents 
associations between prenatal phthalate 
metabolite concentrations (for molar sum 
DEHP and other metabolites) and CBCL 
syndrome scale scores in a combined sam-
ple of boys and girls, as well as sex-stratified 
samples. Table 4 provides this information 
for the CBCL DSM-oriented scale scores. 
Somatic Complaints scores were positively 
associated with urinary concentrations of 
summed DEHP metabolites (β = 0.10; 95% 
CI: 0.01, 0.20, for the association between 
a 1-unit increased in the ln-transformed 
metabolite concentration and the square 
root of the outcome score) in the com-
bined sample of boys and girls (Table 3). 
Sex-specific analyses revealed that boys were 
driving these associations (β = 0.15; 95% 
CI: 0.03, 0.28); the result corresponds to 
a 153% increase in the raw score between 
the 25th and 75th percentile of DEHP 
metabolites (holding all covariates constant 
at their mean value) This association among 
girls was null, and the interaction p-value 
for the difference between boys and girls 
was not significant (pint = 0.25). Summed 
DEHP metabolites were associated with 
lower Anxious/Depressed syndrome scores 
in girls (β = –0.21; 95% CI: –0.38, –0.04; 
corresponding to a 37% reduction from the 
25th to the 75th percentile of exposure) but 
there was no association in boys (pint = 0.04). 
Similarly, we observed negative associa-
tions of summed DEHP metabolites with 
the Anxiety Problems DSM-oriented score 
in girls (β = –0.21; 95% CI: –0.35, –0.06; 
corresponding to 51% reduction from the 
25th to 75th percentile) but not boys 
(pint = 0.01) (Table 4).
Metabolites of DBPs. We observed 
multi ple associations of ln-transformed uri-
nary concentrations of MiBP and MBP, 










California 9 (5.9) 5 (6.5) 4 (5.3)
Minnesota 57 (37.3) 31 (40.3) 26 (34.2)
Missouri 48 (31.4) 22 (28.6) 26 (34.2)
Iowa 39 (25.5) 19 (24.7) 20 (26.3)
Mother’s race/ethnicity
Hispanic/Latina 4 (2.6) 1 (1.3) 3 (3.9)
Non-Hispanic white 141 (92.2) 72 (93.5) 69 (90.8)
Black 5 (3.3) 3 (3.9) 2 (2.6)
Asian 3 (2.0) 1 (1.3) 2 (2.6)
Child age (months) 102.0 ± 12.0 101.8 ± 12.1 102.3 ± 12.0
Mother’s education
< College 23 (15.0) 9 (11.7) 14 (18.4)
≥ College 130 (85.0) 68 (88.3) 62 (81.6)
Mother’s age at enrollment (years) 31.1 ± 4.9 31.1 ± 4.8 31.1 ± 5.1
Family stress during pregnancy 1.4 ± 1.7 1.4 ± 1.7 1.4 ± 1.7
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the two DBPs metabolites, with outcome 
scores in the combined sample of boys and 
girls. Among CBCL syndrome score out-
comes (Table 3), MiBP concentrations were 
associated with higher scores for Attention 
Problems (β = 0.20; 95% CI: 0.01, 0.39) 
and Aggressive Behavior (β = 0.24; 95% CI: 
0.03, 0.45). Among DSM-oriented scale 
scores, MiBP concentrations were associated 
with higher Oppositional/Defiant Problems 
scores (β = 0.19; 95% CI: 0.02, 0.35), and 
both DBPs were associated with higher 
Conduct Problems scores (MiBP: β = 0.22; 
95% CI: 0.05, 0.38; MBP: β = 0.19; 
95% CI: 0.02, 0.37).
Associations that were statistically signifi-
cant in the total sample were stronger in boys 
than in girls, though differences were signifi-
cant for Conduct Problems scores only [e.g., 
for MiBP: β = 0.39; 95% CI: 0.20, 0.58 in 
boys (corresponding to a 260% increase from 
the 25th to 75th percentile) vs. β = 0.00; 
95% CI: –0.21, 0.20 in girls, pint = < 0.001]. 
In addition, MiBP concentrations were posi-
tively associated with scores for Rule-breaking 
Behavior (β = 0.20; 95% CI: 0.01, 0.38), 
externalizing behavior (β = 0.32; 95% CI: 
0.06, 0.58), and total problems (β = 0.42; 
95% CI: 0.05, 0.8) in boys, whereas cor-
responding estimates in girls were close to 
the null (pint = 0.04, 0.10, and 0.13, respec-
tively) (Table 3). We observed no associations 
of either MiBP or MBP with any CBCL 
score in girls.
BzBP metabolite: MBzP. There were no 
statistically significant associations between 
MBzP and CBCL scores in the population 
as a whole, but there was some evidence of 
sex-specific relationships. Among boys, 
MBzP concentrations were associated with 
higher Oppositional/Defiant behavior scores 
[β = 0.16; 95% CI: 0.01, 0.32 (a 50% 
increase from the 25th to 75th percentile)] 
and Conduct Problems [β = 0.21; 95% CI: 
0.06, 0.37 (a 92% increase from the 25th to 
75th percentile)] in boys, whereas associations 
were close to the null for girls (pint = 0.10 and 
0.01, respectively) (Table 4). In girls, MBzP 
concentrations were associated with lower 
scores for syndrome scale Anxious/Depressed 
[β = –0.20; 95% CI: –0.39, –0.01 (a 37% 
decrease from the 25th to 75th percentile)], 
internalizing behavior [β = –0.22; 95% CI: 
–0.44, 0 (a 30% decrease from the 25th to 
75th percentile)], and DSM Anxiety Problems 
scores [β = –0.19; 95% CI: –0.35, –0.03 (a 
51% decrease from the 25th to 75th percen-
tile)], whereas associations were close to the 
null for boys (pint = 0.24, 0.17, and 0.13, 
respectively) (Tables 3 and 4).
DEP metabolite: MEP. Inverse associations 
between MEP urinary concentrations and 
the DSM Affective Problems score were seen 
when both sexes were combined and among 
boys: β = –0.10 (95% CI: –0.19, –0.01) and 
β = –0.12 (95% CI: –0.24, –0.01), respec-
tively. However, the association was null 
among girls (β = –0.08; 95% CI: –0.19, 0.04) 
and the interaction p-value for the differ-
ence between boys and girls was not signifi-
cant (pint = 0.57). None of the CBCL scores 
were significantly associated with MEP 
 concentrations among girls.
Sensitivity analyses. Our sensitivity analy-
sis revealed that the direction and magnitude 
of significant and nonsignificant associations 
were not materially affected by adjusting for 
other phthalate metabolites (data not shown). 
In another sensitivity analysis, we found no 
substantial differences in our results when we 
adjusted for study center; the largest change in 
association magnitude was for the association 
between MiBP and attention problems in the 
combined sample of boys and girls (β = 0.20; 
95% CI: 0.01, 0.39 in original analy-
sis became β = 0.23; 95% CI: 0.03, 0.43). 
Finally, when we restricted our main analysis 
to non-Hispanic white mothers, although the 
overall interpretation of the results did not 
change, a few of the beta estimates changed 
appreciably. Specifically, among the com-
bined sample of boys and girls and focusing 
on MiBP, three CBCL scores lost significance: 
Attention Problems [β = 0.20 (95% CI: 0.01, 
0.39) in original analysis became β = 0.19 
(95% CI: –0.01, 0.40)], Aggressive Behavior 
Table 2. Descriptive statistics for CBCL scores and phthalate metabolites in the final sample (n = 153).
Variable
Both sexes Males Females
Mean ± SD or 
GM (95% CI)








Median (min–max) or 
25th, 75th percentiles
CBCL syndrome scales (raw scores)
Anxious/Depressed 3.1 ± 2.9 2 (0–12) 3.2 ± 2.9 2 (0–11) 2.9 ± 3.0 2 (0–12)
Withdrawn/Depressed 1.0 ± 1.7 0 (0–10) 1.2 ± 1.8 0 (0–8) 0.9 ± 1.5 0 (0–10)
Somatic Complaints 1.4 ± 1.7 1 (0–8) 1.4 ± 1.7 1 (0–8) 1.3 ± 1.7 1 (0–8)
Social Problems 2.0 ± 2.1 1 (0–12) 2.3 ± 2.4 1 (0–12) 1.8 ± 1.7 1 (0–7)
Thought Problems 1.8 ± 2.0 1 (0–11) 2.2 ± 2.3 2 (0–11) 1.4 ± 1.5 1 (0–7)
Attention Problems 3.7 ± 3.4 3 (0–18) 4.7 ± 3.6 4 (0–18) 2.8 ± 2.9 2 (0–12)
Rule-breaking Behavior 1.3 ± 1.6 1 (0–9) 1.7 ± 1.9 1 (0–9) 0.9 ± 1.1 0.5 (0–5)
Aggressive Behavior 3.6 ± 3.7 3 (0–16) 4.3 ± 4.2 3 (0–16) 2.9 ± 3.0 2 (0–14)
Internalizing behavior 5.4 ± 4.9 4 (0–23) 5.7 ± 5.1 5 (0–23) 5.1 ± 4.7 4 (0–21)
Externalizing behavior 4.9 ± 4.9 3 (0–23) 6.0 ± 5.7 4 (0–23) 3.8 ± 3.6 3 (0–16)
Total problems 21.0 ± 15.0 17 (1–70) 23.8 ± 17.2 19 (2–70) 18.0 ± 11.9 15 (1–49)
CBCL DSM scales (raw scores)
Affective Problems 1.2 ± 1.7 1 (0–8) 1.6 ± 2.0 1 (0–8) 0.9 ± 1.3 0 (0–6)
Anxiety Problems 1.5 ± 1.8 1 (0–8) 1.7 ± 1.8 1 (0–7) 1.4 ± 1.8 1 (0–8)
Somatic Problems 0.8 ± 1.5 0 (0–7) 0.8 ± 1.5 0 (0–7) 0.8 ± 1.5 0 (0–7)
ADHD Problems 3.1 ± 2.7 3 (0–11) 3.9 ± 2.8 3 (0–11) 2.3 ± 2.3 2 (0–10)
Oppositional/Defiant Problems 1.9 ± 1.9 1 (0–8) 2.3 ± 2.1 2 (0–8) 1.5 ± 1.6 1 (0–6)
Conduct Problems 1.3 ± 2.0 0 (0–12) 1.9 ± 2.5 1 (0–12) 0.6 ± 1.0 0 (0–3)
Phthalate metabolitesa,b
MEHP 3.65 (2.89, 4.61) 1.1, 9.9 3.52 (2.49, 4.98) 0.8, 6.7 3.79 (2.79, 5.15) 1.2, 10.7
MEHHP 13.04 (10.28, 16.55) 6.1, 24.2 12.49 (9.0, 17.33) 5.5, 24.1 13.63 (9.67, 19.21) 6.3, 27.1
MEOHP 11.50 (9.16, 14.44) 5.1, 22.0 11.19 (8.15, 15.38) 4.7, 21.5 11.82 (8.56, 16.32) 5.2, 24.7
MiBP 2.34 (1.98, 2.78) 1.0, 4.8 2.34 (1.83, 2.99) 1.1, 5.1 2.35 (1.86, 2.97) 1.0, 4.7
MBP 13.61 (11.52, 16.07) 7.8, 29.4 13.36 (10.54, 16.94) 7.3, 29.6 13.86 (11.0, 17.46) 8.4, 28.1
MBzP 6.59 (5.34, 8.15) 3.4, 16.3 6.43 (4.80, 8.61) 2.7, 15.5 6.76 (4.99, 9.16) 4.0, 18.4
MEP 81.01 (62.09, 105.70) 26.2, 231.0 85.66 (59.27, 123.82) 31.0, 307.5 76.56 (52.35, 111.96) 23.2, 168.3
Abbreviations: max, maximum; min, minimum.
aLimit of detection for all metabolites was between 0.95 and 1.07 ng/mL. bNumber of metabolite observations below the LOD in final sample of both sexes: MEHP: n = 32 (20.9%), 
MEHHP: n = 4 (2.6%), MEOHP: n = 5 (3.3%), MiBP: n = 27 (17.6%), MBP: n = 4 (2.6%), MBzP: n = 6 (3.9%), MEP: n = 1 (0.7%).
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[β = 0.24 (95% CI: 0.03, 0.45) in original 
analysis became β = 0.21 (95% CI: –0.01, 
0.43)], and the DSM Oppositional/Defiant 
Problems score [(β = 0.19; 95% CI: 0.02, 
0.35) in original analysis became β = 0.17 
(95% CI: 0, 0.34)]. The association between 
MBP and DSM Affective Problems score 
strengthened and attained statistical sig-
nificance [β = –0.17 (95% CI: –0.34, 0) in 
original analysis became β = –0.21 (95% CI: 
–0.39, –0.03)]. Among MBzP coefficients, 
three associations with the following catego-
ries became more negative and gained statis-
tical significance: syndrome scale Anxious/
Depressed [β = –0.13 (95% CI: –0.28, 
0.03) in original analysis became β = –0.17 
(95% CI: –0.32, –0.01)], DSM-oriented 
Affective Problems [β = –0.12 (95% CI: 
–0.25, 0.01) in original analysis became 
β = –0.14 (95% CI: –0.27, –0.01)], and 
DSM-oriented Anxiety Problems [β = –0.11 
(95% CI: –0.24, 0.02) in original analy-
sis became β = –0.14 (95% CI: –0.27, 0)]. 
Finally, the association between MEP and the 
DSM Affective Problems score became more 
negative and gained significance [β = –0.10 
(95% CI: –0.19, –0.01) in original analysis 
became β = –0.09 (95% CI: –0.19, 0)].
Discussion
In this analysis we examined associations 
between maternal phthalate metabolite uri-
nary concentrations during pregnancy and 
neurobehavioral development in their chil-
dren at ages of 6–10 years. Our analyses 
focused on metabolites of five phthalate esters 
to which exposure is particularly widespread. 
Our results indicated a variety of associations 
between prenatal phthalate exposures and 
behavior syndrome scores based on mater-
nal reports, and many of the associations 
appeared to differ between boys and girls.
A primary source of DEHP exposure is 
through consumption of food, with con-
tamination likely occurring through pack-
ing, storage and processing (Clark et al. 2002; 
Fromme et al. 2007; Rudel et al. 2011). 
DBPs are found in diverse sources such as 
consumer plastics, personal care products, 
and DnBP is also used in the enteric coat-
ing of some medications (Hernandez-Diaz 
et al. 2009). Exposure to BzBP occurs primar-
ily through diet, as well as through products 
such as adhesives, vinyl tile, sealants, car care 
products, and some personal care products 
(CDC 2012b). DEP exposure occurs primar-
ily through use of personal care products, 
cosmetics, and perfumed products (Koniecki 
et al. 2011). Although the production of 
various phthalates is changing (most notably 
the reduction of DEHP and the increase of 
diisononyl phthalate in the European Union), 
exposure to the phthalates we considered 
remains widespread (Goen et al. 2011).
In our analysis, prenatal concentrations 
of DEHP metabolites were associated with 
greater somatic complaints in children. 
Somatic complaints include general physical 
symptoms such as headaches, stomach aches, 
feeling jittery, and muscular tension; the pres-
ence of these symptoms has been previously 
linked with poorer school performance in 
children (Hughes et al. 2008). We also noted 
lower symptoms of anxiety among girls whose 
mothers had higher concentrations of DEHP 
metabolites. To the best of our knowledge, 
ours is the first analysis to report an associa-
tion between prenatal DEHP exposure and 
childhood neurobehavior scores assessed 
through a standardized instrument.
Focusing on magnitudes of associa-
tion, our strongest finding was the associa-
tion of prenatal concentration of DBP 
metabolites with a range of conduct-related 
behavior scores (e.g., Attention Problems, 
Table 3. Regression phthalate metabolite coefficients (with 95% CIs) of models predicting CBCL syndrome scale scores, according to child sex.a
CBCL syndrome 
scales Sex ln(∑DEHP) pintb ln(MiBP) pint ln(MBP) pint ln(MBzP) pint ln(MEP) pint
Anxious/Depressed Overall –0.09 (–0.22, 0.03) 0.04 (–0.16, 0.24) –0.06 (–0.27, 0.15) –0.13 (–0.28, 0.03) –0.05 (–0.16, 0.06)
Male 0.02 (–0.15, 0.18) 0.11 (–0.13, 0.34) 0.01 (–0.25, 0.26) –0.06 (–0.25, 0.13) –0.04 (–0.18, 0.10)
Female –0.21 (–0.38, –0.04)* 0.04 –0.03 (–0.29, 0.22) 0.35 –0.14 (–0.40, 0.12) 0.35 –0.20 (–0.39, –0.01)* 0.24 –0.06 (–0.20, 0.08) 0.81
Withdrawn/
Depressed
Overall 0.01 (–0.10, 0.11) –0.03 (–0.19, 0.14) –0.02 (–0.19, 0.15) –0.06 (–0.18, 0.07) –0.08 (–0.16, 0.01)
Male 0.04 (–0.09, 0.18) –0.01 (–0.21, 0.18) 0.02 (–0.19, 0.23) 0.02 (–0.14, 0.17) –0.05 (–0.17, 0.06)
Female –0.03 (–0.18, 0.11) 0.39 –0.04 (–0.25, 0.17) 0.82 –0.06 (–0.27, 0.15) 0.54 –0.13 (–0.29, 0.02) 0.12 –0.10 (–0.22, 0.02) 0.56
Somatic Complaints Overall 0.07 (–0.04, 0.17) –0.05 (–0.21, 0.11) –0.10 (–0.27, 0.07) –0.04 (–0.16, 0.08) –0.01 (–0.10, 0.07)
Male 0.1 (–0.04, 0.23) –0.03 (–0.23, 0.16) –0.07 (–0.28, 0.13) 0.004 (–0.15, 0.16) 0.03 (–0.08, 0.15)
Female 0.03 (–0.10, 0.17) 0.48 –0.07 (–0.28, 0.13) 0.74 –0.13 (–0.34, 0.08) 0.66 –0.08 (–0.24, 0.07) 0.38 –0.06 (–0.18, 0.05) 0.21
Social Problems Overall –0.07 (–0.18, 0.04) 0.07 (–0.10, 0.24) –0.04 (–0.22, 0.14) –0.04 (–0.17, 0.09) –0.08 (–0.17, 0.01)
Male –0.04 (–0.18, 0.10) 0.18 (–0.02, 0.37) 0.02 (–0.19, 0.24) 0.06 (–0.10, 0.22) –0.06 (–0.18, 0.05)
Female –0.11 (–0.26, 0.03) 0.44 –0.06 (–0.27, 0.16) 0.06 –0.10 (–0.32, 0.11) 0.33 –0.14 (–0.30, 0.02) 0.05 –0.09 (–0.21, 0.03) 0.71
Thought Problems Overall 0.03 (–0.08, 0.14) 0.12 (–0.05, 0.28) –0.02 (–0.20, 0.16) –0.05 (–0.18, 0.08) –0.07 (–0.16, 0.02)
Male 0.07 (–0.07, 0.22) 0.15 (–0.05, 0.35) –0.01 (–0.23, 0.20) –0.06 (–0.22, 0.11) –0.10 (–0.21, 0.02)
Female –0.02 (–0.17, 0.12) 0.31 0.07 (–0.15, 0.29) 0.51 –0.03 (–0.25, 0.19) 0.89 –0.04 (–0.20, 0.12) 0.87 –0.04 (–0.16, 0.08) 0.47
Attention Problems Overall 0.08 (–0.04, 0.21) 0.20 (0.01, 0.39)* 0.06 (–0.14, 0.26) –0.05 (–0.20, 0.10) –0.04 (–0.14, 0.07)
Male 0.07 (–0.10, 0.23) 0.27 (0.04, 0.50)* 0.12 (–0.12, 0.37) 0.003 (–0.18, 0.19) –0.08 (–0.22, 0.06)
Female 0.10 (–0.07, 0.26) 0.77 0.12 (–0.12, 0.36) 0.29 –0.01 (–0.26, 0.25) 0.38 –0.10 (–0.29, 0.08) 0.35 0.01 (–0.13, 0.14) 0.35
Rule-breaking 
Behavior
Overall 0.002 (–0.10, 0.10) 0.09 (–0.06, 0.25) 0.08 (–0.08, 0.25) –0.01 (–0.13, 0.11) 0.01 (–0.08, 0.09)
Male 0.04 (–0.09, 0.17) 0.20 (0.01, 0.38)* 0.14 (–0.05, 0.34) 0.08 (–0.07, 0.23) 0.02 (–0.09, 0.13)
Female –0.04 (–0.18, 0.09) 0.37 –0.04 (–0.23, 0.16) 0.04 0.02 (–0.19, 0.22) 0.28 –0.10 (–0.25, 0.05) 0.06 –0.01 (–0.12, 0.10) 0.67
Aggressive Behavior Overall –0.05 (–0.19, 0.09) 0.24 (0.03, 0.45)* 0.03 (–0.19, 0.25) 0.10 (–0.07, 0.26) –0.06 (–0.18, 0.05)
Male –0.02 (–0.20, 0.15) 0.34 (0.09, 0.59)* 0.12 (–0.15, 0.39) 0.19 (–0.01, 0.40) –0.04 (–0.19, 0.11)
Female –0.08 (–0.26, 0.10) 0.64 0.12 (–0.14, 0.39) 0.16 –0.07 (–0.34, 0.21) 0.24 –0.002 (–0.21, 0.20) 0.11 –0.08 (–0.23, 0.07) 0.70
Internalizing 
behavior
Overall –0.02 (–0.17, 0.13) 0.02 (–0.21, 0.25) –0.08 (–0.33, 0.16) –0.13 (–0.30, 0.05) –0.05 (–0.18, 0.07)
Male 0.09 (–0.1, 0.28) 0.09 (–0.18, 0.37) –0.01 (–0.30, 0.29) –0.04 (–0.25, 0.18) –0.02 (–0.19, 0.14)
Female –0.14 (–0.34, 0.06) 0.08 –0.07 (–0.37, 0.22) 0.32 –0.16 (–0.46, 0.14) 0.37 –0.22 (–0.44, 0)* 0.17 –0.08 (–0.25, 0.08) 0.60
Externalizing 
behavior
Overall –0.04 (–0.18, 0.11) 0.20 (–0.02, 0.42) 0.08 (–0.16, 0.31) 0.07 (–0.10, 0.24) –0.03 (–0.15, 0.09)
Male –0.003 (–0.19, 0.19) 0.32 (0.06, 0.58)* 0.17 (–0.12, 0.45) 0.18 (–0.03, 0.40) –0.02 (–0.18, 0.14)
Female –0.08 (–0.27, 0.12) 0.55 0.06 (–0.22, 0.34) 0.10 –0.02 (–0.31, 0.27) 0.26 –0.04 (–0.25, 0.17) 0.09 –0.05 (–0.21, 0.11) 0.79
Total problems Overall –0.01 (–0.22, 0.20) 0.27 (–0.05, 0.58) –0.004 (–0.34, 0.33) –0.05 (–0.30, 0.19) –0.12 (–0.29, 0.05)
Male 0.07 (–0.19, 0.34) 0.42 (0.05, 0.80)* 0.12 (–0.29, 0.53) 0.10 (–0.20, 0.40) –0.11 (–0.34, 0.11)
Female –0.10 (–0.37, 0.18) 0.33 0.07 (–0.33, 0.47) 0.13 –0.14 (–0.55, 0.28) 0.29 –0.21 (–0.51, 0.10) 0.10 –0.12 (–0.35, 0.10) 0.95
aOutcomes are square root–transformed raw CBCL syndrome scores. Overall estimates are from models adjusted for child sex, child age (months), mother’s education (at least college 
education, yes or no), creatinine, and family stress score. Sex-specific estimates and interaction p-values are from models that include interactions between sex and ln-metabolite 
concentrations, with adjustment for same covariates. bpint, interaction p-value. *p ≤ 0.05.
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Rule-breaking Behavior, Aggressive Behavior, 
Oppositional/Defiant Problems) in boys. One 
prior analysis of 3-year-old children reported 
that prenatal urinary concentrations of indi-
vidual metabolites of DBPs (both DnBP and 
DiBP) were associated with more negative 
internalizing behavior (a summary score 
encompassing Somatic Complaints, Anxious/
Depressed behavior, and Withdrawn/
Depressed behavior) (Whyatt et al. 2012). 
Our results did not support this prior find-
ing. Although our study and Whyatt et al.’s 
(2012) study employed the CBCL inventory, 
we used the edition targeted to children of 
6–10 years of age, whereas their study ana-
lyzed the edition for 1.5- to 5-year-olds. Our 
finding is consistent with another analysis 
that described associations of a measure of 
low-molecular-weight phthalates (which 
included metabolites of DBPs) with higher 
scores on the Behavior Assessment System 
for Children’s externalizing behavior category 
(e.g., increased aggression, inattention, and 
conduct problems) in 4- to 9-year-old boys 
but not among girls (Engel et al. 2010).
The associations we report generally dif-
fered between boys and girls, which is con-
sistent with the two prior studies. Higher 
prenatal urine concentrations of MBzP were 
associated with higher scores for Oppositional/
Defiant Problems and Conduct Problems 
in boys, but not girls, and with lower scores 
for Anxiety Problems in girls but not boys. 
Whyatt et al. (2012) reported that MBzP 
concentrations were associated with higher 
scores for internalizing behaviors such as 
Anxious/Depressed, Withdrawn/Depressed, 
and Somatic Complaints, in girls, but not 
boys. Finally, we found an association of 
greater MEP urinary concentrations with 
fewer Affective Problems symptoms (i.e., 
problems relating to mood, such as depres-
sion, mania, anxiety) in a combined sample of 
boys and girls.
To our knowledge, this is the third 
analysis to date of prenatal phthalate expo-
sure and child behavioral development (Engel 
et al. 2010; Whyatt et al. 2012). Differences 
in study methods and populations may help 
explain differences in findings among the 
studies. Women in our study were older at 
pregnancy, mostly non-Hispanic white, and 
had higher educational attainment than 
women in the other studies. When behavioral 
assessment occurred, our study’s children were 
6–10 years of age, compared with 4–9 years 
(Engel et al. 2010) and 3 years of age (Whyatt 
et al. 2012). There were also key differences 
in study design. Our study employed a mul-
ticenter design, so the population may be 
more geographically representative of the U.S. 
population. Specifically, our study sample 
consisted of California, Minnesota, Missouri, 
and Iowa, whereas the two prior studies drew 
subjects from New York City. SFF women 
gave urine samples at somewhat earlier ges-
tational ages (mean, 26.6 weeks) than those 
in the studies by Engel (31.2 weeks) and 
Whyatt (33.1 weeks). Both our analysis and 
that by Whyatt et al. measured behavior with 
the CBCL, whereas Engel et al. relied on 
the Behavior Rating Inventory of Executive 
Function and the Behavior Assessment System 
for Children–Parent Rating Scales.
Mechanisms that have been proposed for 
potential effects of prenatal phthalates on neu-
rodevelopment are complex and uncertain. 
One previously suggested mechanism involves 
phthalate alteration of thyroid system func-
tion (Engel et al. 2010). In humans, thyroid 
hormones play a crucial role in neurodevel-
opment (Miller et al. 2009), consistent with 
the finding that congenital thyroid  disorders 
are linked with neurodevelopmental deficits 
in children (Oerbeck et al. 2003). Effects of 
phthalate intake on thyroid hormone levels 
have long been observed in animal models 
(Hinton et al. 1986). Urinary concentrations 
of DEHP metabolites were inversely associ-
ated with serum thyroid measures, including 
total and free thyroxine, total triiodothyro-
nine, and thyroglobulin, in an analysis of data 
from adult and adolescent participants in the 
2007–2008 U.S. NHANES (National Health 
and Nutrition Examination Survey) (Meeker 
and Ferguson 2011). This analysis also dem-
onstrated an inverse association between 
mono(3-carboxypropyl) phthalate (a non-
specific metabolite of several high  molecular 
weight phthalates and a minor metabolite 
of DnBP) and total and free thyroxine. In 
a sample study of 76 Taiwanese pregnant 
women, urinary concentrations of DBPs were 
negatively associated with thyroxin and free 
thyroxin (Huang et al. 2007).
A recent study of 845 Danish children 
4–9 years of age in Copenhagen found asso-
ciations between childhood urinary phthal-
ate metabolite concentrations and thyroid 
hormone and IGF-1 (insulin-like growth fac-
tor 1) (Boas et al. 2010). Specifically, metabo-
lites of DEHP were negatively associated with 
IGF-1 among boys, whereas a cumulative 
measure of phthalate exposure (encompassing 
DEHP metabolites, MEP, and MBP) was 
negatively associated with triiodothyronine 
in girls. These sexually dimorphic associa-
tions may provide a possible explanation for 
the observed sexually dimorphic behavioral 
effects. In addition to thyroid system dys-
function, it has been suggested that gesta-
tional exposure to phthalates leads to aberrant 
development of the midbrain dopaminergic 
Table 4. Regression phthalate metabolite coefficients (with 95% CIs) of models predicting CBCL DSM-oriented scale scores, according to child sex.a
CBCL DSM-
oriented scales Sex ln(∑DEHP) pintb ln(MiBP) pint ln(MBP) pint ln(MBzP) pint ln(MEP) pint
Affective 
Problems
Overall –0.06 (–0.17, 0.04) 0.03 (–0.14, 0.19) –0.17 (–0.34, 0) –0.12 (–0.25, 0.01) –0.10 (–0.19, –0.01)*
Male –0.04 (–0.18, 0.10) 0.07 (–0.13, 0.27) –0.15 (–0.36, 0.07) –0.09 (–0.24, 0.07) –0.12 (–0.24, –0.01)*
Female –0.09 (–0.23, 0.06) 0.62 –0.02 (–0.24, 0.19) 0.46 –0.20 (–0.41, 0.02) 0.69 –0.15 (–0.31, 0.01) 0.49 –0.08 (–0.19, 0.04) 0.57
Anxiety Problems Overall –0.08 (–0.19, 0.03) 0.02 (–0.15, 0.19) –0.03 (–0.21, 0.14) –0.11 (–0.24, 0.02) –0.03 (–0.12, 0.07)
Male 0.04 (–0.10, 0.18) 0.11 (–0.09, 0.31) 0.06 (–0.16, 0.27) –0.04 (–0.20, 0.12) –0.01 (–0.13, 0.11)
Female –0.21 (–0.35, –0.06)* 0.01 –0.09 (–0.31, 0.12) 0.10 –0.13 (–0.35, 0.09) 0.15 –0.19 (–0.35, –0.03)* 0.13 –0.04 (–0.16, 0.08) 0.69
Somatic 
Problems
Overall 0.10 (0.01, 0.20)* –0.03 (–0.18, 0.12) –0.07 (–0.22, 0.09) –0.01 (–0.13, 0.10) 0.02 (–0.06, 0.10)
Male 0.15 (0.03, 0.28)* –0.02 (–0.20, 0.16) –0.01 (–0.20, 0.18) 0.04 (–0.10, 0.19) 0.08 (–0.02, 0.19)
Female 0.06 (–0.07, 0.18) 0.25 –0.05 (–0.24, 0.15) 0.81 –0.13 (–0.32, 0.07) 0.31 –0.07 (–0.21, 0.08) 0.22 –0.04 (–0.15, 0.06) 0.07
ADHD Problems Overall 0.03 (–0.08, 0.15) 0.10 (–0.08, 0.27) 0.02 (–0.16, 0.21) 0.02 (–0.12, 0.15) 0.02 (–0.08, 0.11)
Male 0.01 (–0.13, 0.16) 0.13 (–0.08, 0.34) 0.07 (–0.16, 0.29) 0.06 (–0.11, 0.23) –0.03 (–0.16, 0.09)




Overall –0.02 (–0.13, 0.09) 0.19 (0.02, 0.35)* 0.04 (–0.13, 0.22) 0.08 (–0.04, 0.21) –0.04 (–0.13, 0.05)
Male 0.003 (–0.14, 0.15) 0.27 (0.07, 0.46)* 0.14 (–0.07, 0.36) 0.16 (0.01, 0.32)* –0.02 (–0.13, 0.10)
Female –0.05 (–0.19, 0.10) 0.57 0.09 (–0.12, 0.30) 0.14 –0.06 (–0.28, 0.15) 0.10 0.0002 (–0.16, 0.16) 0.10 –0.06 (–0.18, 0.06) 0.57
Conduct 
Problems
Overall 0.01 (–0.10, 0.11) 0.22 (0.05, 0.38)* 0.19 (0.02, 0.37)* 0.07 (–0.06, 0.2) –0.01 (–0.10, 0.08)
Male 0.07 (–0.07, 0.21) 0.39 (0.20, 0.58)* 0.36 (0.15, 0.56)* 0.21 (0.06, 0.37)* 0.06 (–0.06, 0.18)
Female –0.07 (–0.21, 0.08) 0.14 –0.004 (–0.21, 0.20) < 0.001 0.02 (–0.19, 0.23) 0.01 –0.07 (–0.23, 0.09) < 0.001 –0.08 (–0.20, 0.04) 0.08
aOutcomes are square root–transformed raw CBCL syndrome scores. Overall estimates are from models adjusted for child sex, child age (months), mother’s education (at least college 
education, yes or no), creatinine, and family stress score. Sex-specific estimates and interaction p-values are from models that include interactions between sex and ln-metabolite 
concentrations, with adjustment for same covariates. bpint, interaction p-value. *p ≤ 0.05.
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system and hyperactivity in rats (Tanida 
et al. 2009). Dopaminergic signaling is 
known to play a role in the pathogenesis of 
ADHD (Del Campo et al. 2011), suggest-
ing that phthalate-induced alteration to this 
pathway may account for our observed asso-
ciation between phthalates and attentional 
behavior scores.
Our observation that individual phthal-
ate metabolites differentially correlate with 
behavior is consistent with several other 
studies (Engel et al. 2010; Swan et al. 2005; 
Whyatt et al. 2012). This may be explained 
by differences in routes of exposure or rates of 
metabolism and excretion (Frederiksen et al. 
2007). These inconsistencies might also partly 
reflect random error, because we estimated a 
very large number of associations, and at least 
some may have occurred by chance.
Our analysis also has some limitations. 
First, we obtained only one prenatal urine sam-
ple. Had we been able to analyze several sam-
ples collected at different time points, we might 
have been able to estimate fetal exposure to 
phthalates more accurately or possibly identify 
a critical developmental window with regard 
to phthalate effects and child behavior. Several 
studies have shown that the intraclass correla-
tion coefficient (ICC)—a measure of repro-
ducibility—of phthalate metabolite urinary 
concentrations varies across metabolites (Adibi 
et al. 2008; Hauser et al. 2004; Peck et al. 
2010). Collectively, these studies suggest that 
urinary concentration ICCs are low for DEHP 
metabolites and moderate for the metabolites of 
DBPs, with some conflicting results for MEP. 
This type of misclassification of phthalate expo-
sure (error due to low reproducibility) would be 
expected to bias our findings toward the null. 
However, other potential sources of bias, such 
as uncontrolled confounding, could cause bias 
in various directions.
Second, the clinical significance of the 
associations we estimated is unknown. The 
square root–transformed raw scores of the 
CBCL do not correspond to clinically relevant 
developmental outcomes, but instead were 
intended to capture statistical differences in a 
research context. However, it is understood 
that although small shifts in the population 
distribution of continuous health measures 
may not be meaningful at the individual level, 
these can take on considerable public health 
significance at the tails of the distribution, 
particularly when shifts are a consequence of 
common exposures (Bellinger 2004).
Third, we were unable to adjust for sev-
eral potentially confounding variables such as 
mother’s race. We chose to statistically adjust 
only for covariates with sufficient variability. 
Adjusting for covariates with little variability 
would have produced imprecise estimates and 
decrease the degrees of freedom (which were 
critical, considering our small sample size). 
We cannot rule out the potential for bias due 
to uncontrolled confounding.
Fourth, our analysis relied on a small sam-
ple size, and the representativeness of our final 
sample is unclear. Although phthalate metabo-
lite concentrations did not differ significantly 
between our final sample and a subsample 
that included 80% of the initial sample of eli-
gible mothers, women in the final sample were 
of higher socioeconomic status. The school-
age CBCL we employed was normed using 
a national sample of 1,753 children between 
the ages of 6 and 18 years (Achenbach and 
Rescorla 2001). The T-score percentiles we 
observed suggest that our sample had slightly 
more behavioral problems than the norma-
tive sample. The prenatal phthalate metabolite 
concentrations we observed in this population 
were all lower than those reported in Wyatt 
et al. (2012), yet were comparable to those we 
previously observed in a nationally represen-
tative sample of women of reproductive age 
(Kobrosly et al. 2012).
Conclusions
Our results suggest associations between expo-
sure to certain phthalates in late pregnancy 
and behavioral problems, many of which 
appeared to be specific to boys or stronger 
in boys than girls. Given the few studies on 
this topic and the methodological and study 
population differences between these studies, 
additional research is clearly warranted.
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